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EXAMINING INFLAMMATORY MECHANISMS AND POTENTIAL 
CYTOPROTECTIVE THERAPEUTICS IN ANIMAL MODELS OF SHIGA TOXIN 
INDUCED KIDNEY INJURY 
BENJAMIN CHO LEE 
ABSTRACT 
Shiga toxin-producing enterohemorrhagic Escherichia coli (EHEC) is an 
emerging food- and water-borne pathogen, causing approximately 73,000 annual 
infections in the United States and an estimated 1.5 million infections globally. E. 
coli O157:H7, the most frequently associated EHEC strain, is primarily 
transmitted through consumption of contaminated ground beef and produce and 
leads to hemorrhagic colitis in humans. In 5% to 15% of infected patients, 
circulating Shiga toxins (Stx1, Stx2) cause hemolytic uremic syndrome (HUS), 
characterized by the presence of thrombocytopenia, hemolytic anemia, and 
thrombotic microangiopathy, contributing to acute kidney injury (AKI). Current 
treatment is supportive and antibiotic therapy is contraindicative as it increases 
toxin production. Therapeutics for EHEC-induced HUS need to be identified to 
minimize kidney injury and uncontrolled coagulopathy. Well-characterized animal 
models of HUS and EHEC infection are available and provide avenues for 
potential therapeutic discovery. Baboons (Papio) challenged with endotoxin-free 
Shiga toxins develop full spectrum HUS, and mice infected with Stx2-producing 
Citrobacter rodentium (Cr Stx2+), a genetically modified enteric mouse pathogen, 
	  	  	   vii 
develop severe Stx2-mediated kidney injury. Initial studies have shown that 
soluble thrombomodulin (sTM), an anti-coagulant, is a promising therapeutic in 
preventing severe kidney injury in pediatric patients.  In these studies, we 
determined whether complement was activated in baboons challenged with 
Shiga toxins, and evaluated whether intraperitoneal injection of sTM would 
reduce disease severity from mice infected with Cr Stx2+. D-dimer and cell injury 
markers (HMGB1, histones) confirmed the presence of coagulopathy and cell 
injury in Stx challenged baboons. Studies revealed that complement activation is 
not required for the development of thrombotic microangiopathy and HUS 
induced by EHEC Shiga toxins in these pre-clinical models. Soluble 
thrombomodulin treatment in Cr Stx2+ infected mice significantly decreased 
colonization but did not alter mortality. However, gene expression of kidney injury 
markers (NGAL, KIM-1) decreased significantly compared to no treatment 
indicating sTM-associated cytoprotectivity. The C. rodentium mouse model does 
not develop the coagulopathy seen in HUS patients and sTM treatment may be 
more effective in the baboon toxemia model. Soluble thrombomodulin is a 
promising therapeutic for EHEC-induced HUS and should be further evaluated in 
Stx challenged baboons. 
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CHAPTER ONE 1	  
INTRODUCTION 2	  
1.1 Importance 3	  
 Shiga toxin-producing enterohemorrhagic Escherichia coli (EHEC) is an 4	  
emerging food- and water-borne pathogen, causing approximately 73,000 annual 5	  
infections in the United States and an estimated 1.5 million infections globally 6	  
(Frenzen et al, 2005; Stearns-Kurosawa et al, 2013). Infection with the most 7	  
common EHEC strain, E. coli O157:H7, costs an annual  $405 million (in 2003 8	  
dollars), including $370 million in premature deaths, $30 million in medical care, 9	  
and $5 million in lost productivity (Frenzen et al, 2005). It is primarily transmitted 10	  
to humans through consumption of undercooked ground meat products, raw milk, 11	  
and contaminated raw vegetables. EHEC infection can cause diarrhea and 12	  
hemorrhagic colitis in humans. Shiga-like toxins (Stx1 and Stx2) bind to Gb3 13	  
expressing endothelial cells, particularly in renal glomeruli, to elicit their ribosome 14	  
inactivating function (Johannes et al, 2010). Hemolytic uremic syndrome (HUS) is 15	  
a severe clinical complication that develops in 5% to 15% of infected patients, 16	  
characterized by hemolytic anemia, thrombocytopenia, and thrombotic 17	  
microangiopathy, resulting in acute renal failure and death (Mayer et al, 2012).   18	  
 Escherichia coli O157:H7 was first recognized as a pathogen in 1982 19	  
during an outbreak of hemorrhagic colitis in 47 patients in Oregon and Michigan 20	  
(Riliey et al, 1983). It was not until 1993 that E. coli O157:H7 was recognized as 21	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an important and threatening pathogen after a multistate outbreak was linked to 22	  
undercooked ground beef patties sold from a fast-food restaurant chain and 23	  
hospitalized 501 patients (Bell et al, 1994). From 1982 to 2002, there were 350 24	  
outbreaks (≥ 2 cases of same epidemiologic source) reported to the CDC from 49 25	  
states, and during that period, 17.4% out of the total 8,598 infected individuals 26	  
required hospitalization (Bell et al, 1994). Food was the predominant 27	  
transmission route from 1982 to 2002 and accounted for 61% of outbreak-related 28	  
cases (Bell et al, 1994). 29	  
 30	  
1.2 Escherichia Coli 31	  
Escherichia coli is a Gram negative, rod shaped bacteria in the family 32	  
Enterobacteriaceae. E. coli is part of the normal human commensal found in the 33	  
intestinal tract but introduction to pathogenic serotypes including E. coli O157:H7 34	  
and O104:H4 can cause severe complications and death (Karch et al, 2012; 35	  
Mayer et al 2012). Although the reservoir of E. coli O104:H4 is not yet known, the 36	  
key reservoir for E. coli O157:H7 are ruminants, particularly cattle (Croxen et al, 37	  
2010; Johannes et al, 2010). Infected cattle are asymptomatic and shed EHEC in 38	  
their feces, which can contaminate bovine products and produce (Cray et al, 39	  
1995). Human transmission mainly occurs from consumption of contaminated 40	  
food and water. Based on in vitro and animal model studies, several virulence 41	  
factors have been identified, the major factor being Shiga-like toxins (Boerlin et 42	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al, 1999; Law, 2001).  EHEC have not acquired entero-invasive properties 43	  
needed for bacteremia and secreted Shiga toxins are responsible for severe 44	  
organ damage (Taylor, 2008). 45	  
 46	  
1.3 Shiga Toxins  47	  
Shiga toxins from EHEC strains were first recognized to be associated 48	  
with HUS in 1983 (Karmali et al, 1983). Shiga toxins produced by EHEC have 49	  
similar functional and structural properties to Shiga toxin expressed by Shigella 50	  
dysenteriae serotype 1 (Calderwood et al, 1987). Stx1 differs by one amino acid 51	  
to Stx from S. dysenteriae, and shares 58% amino acid identity to EHEC Stx2 52	  
(Calderwood et al, 1987). There have been a number of Shiga toxin variants 53	  
identified, and Stx2 has been epidemiologically linked to increased severity in 54	  
disease (Boerlin et al, 1999).  55	  
 Shiga toxins 1 and 2 are multi subunit AB5 protein complexes composed 56	  
of an enzymatic A subunit non-covalently associated with a receptor-binding 57	  
pentamer B subunit (Fraser et al, 1994). The pentameric B subunit binds to cell 58	  
surface globotriaosylceramide (Gb3) receptors found on certain eukaryotic cell 59	  
types primarily in the two principal target organs, kidney and brain (Trachtman et 60	  
al, 2012). The primary cell target of Shiga toxin toxicity in humans and non- 61	  
human primates are the renal glomerular endothelial cells, whereas renal corticol 62	  
and medullary tubular epithelial cells are targeted in mice (Psotka et al, 2009; 63	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Trachtman et al, 2012; Stearns-Kurosawa et al, 2013). Following Gb3 receptor 64	  
binding, Shiga toxin-receptor complexes are endocytosed into the target cell and 65	  
undergo retrograde transport to the endoplasmic reticulum via the Golgi 66	  
apparatus (Sandvig et al, 1992). The A subunit N-glycosidase removes an 67	  
adenine base from the 28S ribosomal RNA leading to inhibition of protein 68	  
synthesis and ER stress (Iordanov et al, 1997). Shiga toxins have been shown to 69	  
induce inflammation in patients and animal models, in addition to the 70	  
complications seen in the kidneys, intestines, vasculature, and central nervous 71	  
system (Mayer et al, 2012). 72	  
 73	  
1.4 Hemolytic Uremic Syndrome 74	  
Hemolytic uremic syndrome is defined as the triad of hemolytic anemia, 75	  
thrombocytopenia, and thrombotic microangiopathy that contributes to acute 76	  
kidney injury that may progress to acute renal failure and death (Mayer et al, 77	  
2012). Early symptoms of EHEC infection include watery diarrhea and abdominal 78	  
cramps that can progress to hemorrhagic colitis. The incubation period range 79	  
from three to eight days, and most patients recover within ten days. Epidemiology 80	  
studies have shown that HUS typically develops in approximately 5%-15% of 81	  
infected patients (Tarr et al, 2005). Children, elderly, and the 82	  
immunocompromised are the most susceptible to complications and death from 83	  
EHEC infection (Gould et al, 2009). 84	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 Treatment of HUS is generally supportive and includes managing fluid 85	  
levels, balancing electrolyte levels, and acute renal replacement therapy 86	  
(Goldwater et al, 2012). No toxic specific treatments are available yet and 87	  
antibiotics are usually contraindicated, depending on serotype (Mayer et al, 88	  
2012). Wong et al (2012) demonstrated in a multi-state prospective study of 259 89	  
US children with HUS from E. coli O157:H7 that exposure to antibiotics during 90	  
the first week of illness tripled the risk of developing HUS. For E. coli O157:H7, 91	  
antimicrobials were shown to induce Stx2 expression (up to 140-fold) due to the 92	  
location of Stx genes within the antibiotic inducible resident lambdoid prophages 93	  
(Kimmitt et al, 2000).  94	  
 95	  
1.7 Specific Aims and Hypothesis 96	  
In these studies, we aim to: 97	  
(1) CHAPTER TWO: Determine whether complement is activated in Stx- 98	  
challenged non-human primates during the development of HUS and acute renal 99	  
failure. 100	  
(2) CHAPTER THREE: Examine the effects of soluble thrombomodulin 101	  
treatment on mice infected with Stx2-producing Citrobacter rodentium. 102	  
 We expect these studies to show: 103	  
	  	  	   6 
 (1) CHAPTER TWO: Development of HUS in non-human primates will 104	  
present with activated complement similar to clinical observations seen in 105	  
patients with EHEC induced HUS. 106	  
 (2) CHAPTER THREE: Treatment with soluble thrombomodulin will 107	  
provide positive outcomes versus no treatment in mice as it has been shown as a 108	  
promising therapeutic in patients with EHEC induced HUS. 109	  
  110	  
	  	  	   7 
CHAPTER TWO 111	  
QUIESCENT COMPLEMENT IN NONHUMAN PRIMATES DURING E. 112	  
COLI SHIGA TOXIN-INDUCED HEMOLYTIC UREMIC SYNDROME AND 113	  
THROMBOTIC MICROANGIOPATHY 114	  
 115	  
(Published: Lee BC, Mayer CL, Leibowitz, CS, Stearns-Kurosawa, DJ, Kurosawa 116	  
S. Blood 2013; 122: 803-806.) 117	  
 118	  
2.1 Key Points 119	  
• Complement activation is not required for development of thrombotic 120	  
microangiopathy and HUS induced by EHEC Shiga toxins in non-human 121	  
primates 122	  
• Complement is an important defense mechanism and benefits or risks of 123	  
therapeutic inhibition should be studied further for this infection 124	  
 125	  
2.2 Abstract 126	  
Enterohemorrhagic Escherichia coli (EHEC) produce ribosome inactivating Shiga 127	  
toxins (Stx1, Stx2) responsible for development of hemolytic uremic syndrome 128	  
(HUS) and acute kidney injury (AKI).  Some patients show evidence of 129	  
complement activation during EHEC infection, raising the possibility of 130	  
therapeutic targeting of complement for relief. Our juvenile non-human primate 131	  
	  	  	   8 
(Papio baboons) models of endotoxin-free Stx challenge exhibit full spectrum 132	  
HUS including thrombocytopenia, hemolytic anemia, and AKI with glomerular 133	  
thrombotic microangiopathy. There were no significant increases in soluble 134	  
terminal complement complex (C5b-9) levels after challenge with lethal Stx1 135	  
(n=6) or Stx2 (n=5) in plasma samples from T0 to euthanasia at 49.5-128 hrs 136	  
post-challenge. D-dimer and cell injury markers (HMGB1, histones) confirmed 137	  
coagulopathy and cell injury. Thus, complement activation is not required for the 138	  
development of thrombotic microangiopathy and HUS induced by EHEC Shiga 139	  
toxins in these pre-clinical models, and benefits or risks of complement inhibition 140	  
should be studied further for this infection. 141	  
 142	  
2.3 Introduction   143	  
Shiga toxin-producing enterohemorrhagic Escherichia coli (EHEC) is an 144	  
emerging food- and water-borne pathogen (Mayer et al, 2012). The E.coli 145	  
O157:H7 is the most common strain and its ribosome inactivating Shiga toxins 146	  
(Stx1, Stx2) injure receptor-bearing endothelial cells, particularly in renal 147	  
glomeruli.  Hemolytic uremic syndrome (HUS) is a clinically important 148	  
complication in 5-15% of these patients, characterized by hemolytic anemia, 149	  
thrombocytopenia and thrombotic microangiopathy, often resulting in severe 150	  
acute kidney injury necessitating dialysis.  Antibiotics increase HUS risk (Wong et 151	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al, 2012), and this pathogen is the leading cause of acute renal failure in 152	  
otherwise healthy US children. 153	  
The clinical presentation of EHEC-HUS overlaps that of atypical HUS 154	  
(aHUS), a rare disease induced by genetic abnormalities resulting in unchecked 155	  
alternative complement pathway activation (Noris et al, 2010). Immuno-inhibition 156	  
of complement C5 activation in aHUS patients with Eculizumab (Solaris®) 157	  
reduces levels of inflammatory complement mediators and the terminal 158	  
complement complex (TCC, soluble C5b-9), and normalizes clinical indicators 159	  
(Nurnberger et al, 2009). The clinical similarity of these syndromes has led to 160	  
considerable discussion in the EHEC field about whether Stx activities activate 161	  
complement, which then becomes a major driving force for HUS development.  In 162	  
vitro and murine data support complement activation (Morigi et al, 2011; Noris et 163	  
al, 2012; Thurman et al, 2009), but in vitro data arise from toxin challenges  164	  
~500,000 times higher than the 5-20 pg/ml Stx levels observed in infected 165	  
children (Lopez et al, 2012). Eculizumab was seemingly beneficial in three 166	  
children with severe EHEC-HUS (Lapeyraque et al, 2011), but apparent efficacy 167	  
may have been coincident with natural recovery as suggested by already rising 168	  
platelets and falling LDH levels. Despite these indicators, a direct exploration of 169	  
whether Stx-induced complement activation is responsible for HUS has not been 170	  
done. Our nonhuman primate models of endotoxin-free Stx1 and Stx2 challenge 171	  
present with the full spectrum of human EHEC-HUS including hematology, 172	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physiology, and inflammation responses (Stearns-Kurosawa et al, 2010; Stearns- 173	  
Kurosawa et al, 2011), with glomerular thrombotic microangiopathy (Stearns- 174	  
Kurosawa et al, 2013). Here we examined whether complement was activated in 175	  
the Stx-challenged baboons during the development of HUS and acute renal 176	  
failure. We quantified D-dimer as a marker of fibrinolysis, as well as cell injury 177	  
markers HMGB1 and histones.  178	  
 179	  
2.4 Methods 180	  
2.4.1 Baboon Samples 181	  
Methods and characterization of the nonhuman primate (juvenile Papio baboons, 182	  
4~6kg) challenges with lethal Stx1 (100ng/kg) or Stx2 (50ng/kg) are described 183	  
(Stearns-Kurosawa et al, 2010; Stearns-Kurosawa et al, 2011). All animals 184	  
developed HUS with thrombotic microangiopathy and progressive loss of renal 185	  
function. Animal studies were performed under the oversight of the regulatory 186	  
IACUC and IBC of the Boston University School of Medicine.   187	  
 188	  
2.4.2 ELISA Assays 189	  
Baboon EDTA-plasma or urine (Foley catheter; 20 minute timed samples 190	  
after bladder purge) stored at -80oC were used. Terminal complement complex 191	  
(TCC) was quantified using the Human Terminal Complement Complex ELISA kit 192	  
(Hycult Biotech, Plymouth Meeting, PA). D-dimer was quantified using 193	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Asserachrom D-DI kit (Diagnostica Stago, Parsippany, NJ). HMGB1was 194	  
quantified using HMGB1 ELISA (IBL International, Hamburg, Germany) and 195	  
histones by using Cell Death Detection ELISA plus (Roche Inc., Indianapolis, IN).  196	  
Stored EDTA-plasma from bacteremic baboons challenged intravenously with 197	  
sub-lethal 5x109 CFU/kg E. coli B7 O86a:K61 (SLEC; not toxigenic)(Taylor et al, 198	  
2000) or lethal 3x109 CFU/kg Bacillus anthracis Sterne strain 34F2 (vaccine 199	  
strain) (Stearns-Kurosawa et al, 2006) were positive controls. Data were 200	  
analyzed for differences between groups using Student’s T-test, assuming equal 201	  
variance.    202	  
 203	  
2.5 Results and Discussion 204	  
Bacteremia is rare in patients with EHEC infection and the Shiga toxins 205	  
are widely acknowledged as the primary mediators of organ injury (Sauter et al, 206	  
2008; Mallick et al, 2012). Our nonhuman primate models are the only animal 207	  
models to date that present with full spectrum HUS induced by only Stx 208	  
challenge. Some differences are observed between the toxins with respect to 209	  
timing and inflammation (Stearns-Kurosawa et al, 2010) or renal pathology 210	  
(Stearns-Kurosawa et al, 2013), but the classic triad of hemolytic anemia, 211	  
thrombocytopenia and thrombotic microangiopathy with acute kidney injury are 212	  
shared responses after Stx1 or Stx2. Given the success of complement inhibition 213	  
in aHUS patients, we measured soluble TCC in our Stx-HUS models to 214	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determine whether complement is activated and, if so, when. There were no 215	  
significant increases in soluble TCC levels in animals after lethal challenge with 216	  
Stx1 (Fig 2.1A; n=6) or Stx2 (Fig 2.1B; n=5) up until the time of euthanasia at 217	  
49.5-128 hours post-challenge. Platelet levels declined (Fig 2.1C,D) and 218	  
fibrinogen levels were steady or increased (Fig 2.1E,F) as expected during 219	  
development of HUS. Renal glomerular thrombotic microangiopathy was 220	  
observed by pathology evaluation after necropsy (Stearns-Kurosawa et al, 2013) 221	  
and progressively increasing D-dimer levels (Fig 2.1G,H) confirm coagulation 222	  
activation and subsequent fibrinolysis. The lack of complement activation was 223	  
surprising, given the known crosstalk between coagulation and complement 224	  
pathways (Oikonomopoulou et al, 2012) and markers of complement activation in 225	  
some EHEC-HUS patients (Noris et al, 2012; Thurman et al, 2009). To confirm 226	  
integrity of the assays with baboons, the well-characterized baboon model of 227	  
E.coli bacteremia sepsis with disseminated intravascular coagulation (DIC) was 228	  
evaluated similarly (Silasi-Mansat et al, 2010; Taylor et al, 2000; Taylor et al, 229	  
2001). Sub-lethal challenge with this E.coli strain induced complement activation 230	  
and DIC as judged by thrombocytopenia, fibrinogen consumption, and rapid 231	  
increases in D-dimer (Fig 2.1A,C,E,G). Complement inhibition after high dose of 232	  
this E.coli strain in baboons significantly reduces the consumptive coagulopathy 233	  
and inflammation (Silasi-Mansat et al, 2010). Similarly, soluble TCC in a baboon 234	  
challenged with i.v. Gram positive attenuated Bacillus anthracis (Stearns- 235	  
	  	  	   13 
Kurosawa et al, 2006) peaked at 2,204.99 mAU/ml by 10 hours post-challenge, 236	  
slowly declining over the next 4 days (Fig 2.1A).    237	  
Markers of cell damage also were evaluated in the Stx-challenged 238	  
baboons to confirm systemic cytotoxic activities. HMGB1 and histones are 239	  
damage associated molecular patterns (DAMPs), which are released into the 240	  
circulation by dead or dying cells.  They can engage receptors on distant cells 241	  
and are pro-inflammatory in murine and baboon sepsis models (Xu et al, 2009). 242	  
Both DAMPs were detected in baboon plasma and urine after Stx challenge (Fig 243	  
2.2) with generally earlier rises after Stx1, consistent with earlier increases in 244	  
inflammation cytokines and chemokines (Stearns-Kurosawa et al, 2010). 245	  
 Collectively the data show that the complement pathway is not activated to 246	  
any great extent in this animal model of HUS despite challenge with sufficient Stx 247	  
to induce coagulation, fibrinolysis, cell injury and ultimately death. Mice infected 248	  
with Citrobacter rodentium expressing Stx2 develop EHEC-like intestinal 249	  
adhesion and inflammatory lesions with Stx-induced acute kidney injury, but also 250	  
do not show evidence of complement activation (Mallick et al, 2012). Yet 251	  
complement activation is reported in some EHEC-HUS patients.   It is not clear 252	  
whether Eculizumab was effective during the German 2011 outbreak (Menne et 253	  
al, 2012; Trachtman et al, 2012), but this was an enteroaggregative E.coli 254	  
O104:H4 strain that acquired both Stx2 expression and unusual virulence in 255	  
young adults with differing clinical presentation from more typical 256	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enterohemorrhagic strains (Ullrich et al, 2013). Our baboon HUS models are 257	  
induced by Stx challenge, not an enteric bacterial infection, and bacterial 258	  
translocation from the intestines is not observed in the baboons (Sursal et al, 259	  
2013). Yet there is considerable intestinal injury in EHEC patients that may 260	  
contribute to complement activation.  The colon can be affected with edema, 261	  
hemorrhage and leukocytosis, consistent with the hemorrhagic colitis that is often 262	  
seen preceding HUS, but severity may vary widely between patients.  While our 263	  
data do not support a major role for activation of complement during Stx-induced 264	  
HUS pathogenesis, other host or bacterial virulence factors (Orth et al, 2010) 265	  
may be important, either alone or in combination with the bacterial toxins.  266	  
Complement is a fundamental bacterial defense mechanism and further research 267	  
is warranted to judge therapeutic risks or benefits of modulating this arm of innate 268	  
immunity in EHEC patients. 269	  
 270	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 278	  
Figure 2.1.  Changes in complement and coagulation activation markers.  279	  
Stored timed EDTA-plasma samples from baboons challenged with i.v. 100ng/kg 280	  
Stx1 ( p , left; n=6) or  50ng/kg Stx2 (", right; n=5) were evaluated by ELISA for  281	  
levels of  (A,B) soluble terminal complement complex (TCC, C5b-9) and D-dimer 282	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(G,H). After toxin, the thrombocytopenia (C,D) and steady or increasing 283	  
fibrinogen levels (% change from T0; E,F) are consistent with development of 284	  
hemolytic uremic syndrome and acute kidney injury in these models. In contrast, 285	  
bacteremia  induced by i.v. challenge with pathogenic E.coli (¡, A-G) or 286	  
attenuated B.anthracis (dashed ", A), resulted in rapid and robust rises in 287	  
complement activation accompanied by increased D-dimer and consumption of 288	  
platelets and fibrinogen, consistent with disseminated intravascular coagulation.  289	  
Means are plotted with individual animal values to show variability between 290	  
animals. Significant differences from T0 (mean of each Stx group): *p<0.05, 291	  
**p<0.01, ***p<0.001 292	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 293	  
Figure 2.2.  Cell injury markers.  Challenge of baboons with lethal Stx1 (p , 294	  
left) or Stx2 (", right) led to increases in plasma and urine levels of HMGB1 (A-D) 295	  
and histones (E-H). Stx1 led to earlier and higher levels, consistent with a more 296	  
pro-inflammatory environment after this toxin (Stearns-Kurosawa et al, 2010). 297	  
Plasma HMGB1 increased modestly after i.v. challenge with pathogenic E.coli 298	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(¡, A), returning to baseline values within 2 days after this sub-lethal challenge.  299	  
Means are plotted with individual animal values to show variability.   300	  
 301	  302	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CHAPTER THREE 303	  
EXAMINING THE EFFECTS OF SOLUBLE THROMBOMODULIN 304	  
TREATMENT IN A MURINE MODEL OF EHEC INFECTION 305	  
 306	  
3.1 Introduction   307	  
Thrombomodulin (TM) is a transmembrane protein expressed on the 308	  
surface of endothelial cells and plays important roles in both coagulation and 309	  
inflammation (Weiler et al, 2003). TM is composed of five structural domains: N- 310	  
terminal C-type lectin-like domain, EGF-like domain, O-glycosylation-rich domain, 311	  
transmembrane domain, and the short cytoplasmic domain (Ito et al, 2011). The 312	  
EGF-like domain mediates TM-thrombin binding and is a critical domain for 313	  
anticoagulant activity (Dittman et al, 1990). The TM-thrombin complex activates 314	  
protein C to produce activated protein C (APC), which, in the presence of protein 315	  
S, inactivates factors VIIIa and Va, thereby inhibiting further thrombin formation 316	  
and shifting to an anti-coagulant environment (Yamakawa et al, 2011).  317	  
Thrombomodulin has been shown to play an important role in the 318	  
attenuation of the inflammatory response through APC-dependent and APC- 319	  
independent mechanisms. The anti-inflammatory properties of the C-type lectin- 320	  
like domain of TM are considered APC-independent since this domain is 321	  
dispensable for APC generation (Ito et al, 2011). TM binds to C3b and factor H 322	  
and negatively regulates complement by promoting complement factor I- 323	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mediated inactivation of C3 (Delvaeye et al, 2009). TM also inactivates 324	  
anaphylatoxins C3a and C5a by stimulating activation of thrombin-activatable 325	  
fibrinolysis inhibitor (TAFI) (Oikonomopoulou et al, 2011). The lectin-like domain 326	  
also binds to Lewis Y antigen in lipopolysaccharide (LPS) and neutralizes 327	  
inflammatory responses induced by LPS and Gram-negative bacteria (Shi et al, 328	  
2008). Abeyama et al (2005) reported that the lectin-like domain of TM 329	  
sequesters high mobility box 1 (HMGB1), a molecule with potent cytokine-like 330	  
activity, and interferes with its pro-inflammatory activities. TM further reduces the 331	  
pro-inflammatory activity of HMGB1 by enhancing the thrombin-mediated 332	  
proteolytic degradation of HMGB1 (Ito et al, 2008). One of the major mechanisms 333	  
that amplifies inflammation is through nuclear factor kappa-light-chain-enhancer 334	  
of activated B cells (NF-kB) activation and nuclear translocation from the cytosol 335	  
(White et al, 2000; Joyce et al, 2002). APC decreases NF-kB activation and 336	  
nuclear translocation and leads to reduce synthesis of a variety of inflammatory 337	  
mediators including pro-inflammatory cytokine production (Esmon, 2012). APC 338	  
has also been shown to exert cytoprotective effects including anti-apoptotic 339	  
activity and endothelial barrier stabilization (Ito et al, 2011). These cytoprotective 340	  
effects are mainly mediated by protease activated receptor-1 (PAR-1) and 341	  
endothelial protein C receptor (EPCR) expressed on the surface of endothelial 342	  
cells and leukocytes (Griffin et al, 2007). 343	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Recombinant human soluble thrombomodulin (sTM) is currently approved 344	  
for clinical treatment of disseminated intravascular coagulation (DIC) in Japan. 345	  
Two recent studies successfully treated pediatric patients who developed EHEC- 346	  
induced HUS using sTM as a therapeutic (Honda et al, 2013; Kawasaki et al, 347	  
2013). Both Honda et al (2013) and Kawasaki et al (2013) observed improved 348	  
renal function from sTM treatment and reported increased urine output, 349	  
decreased serum creatinine, decreased proteinuria and hematuria, and 350	  
normalization of coagulation related markers. In both cases, no adverse effects, 351	  
including hemorrhaging or liver dysfunction, were observed. 352	  
Nonhuman primates that developed Stx2-induced HUS had increased 353	  
levels of pro-inflammatory cytokines and chemokines in plasma and urine 354	  
(Stearns-Kurosawa et al, 2010; Stearns-Kurosawa et al, 2013). A recent mouse 355	  
model of EHEC infection was developed by genetically modifying Citrobacter 356	  
rodentium to express Stx2 (Mallick et al, 2012). C. rodentium is a natural mouse 357	  
pathogen that is related and used to study E. coli infection due to the its ability to 358	  
develop attaching and effacing (A/E) lesions with the intestinal epithelium (Mundy 359	  
et al, 2005). Although this model does not develop the full requirements to be 360	  
defined as HUS, infected mice do develop Stx-mediated disease from intestinal 361	  
colonization (Mallick et al, 2012). The Stx2-producing C. rodentium provides a 362	  
model for EHEC colonization and toxin-mediated disease in mice and better 363	  
mimics the colonization observed in humans (Mallick et al, 2012). 364	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Our lab has adopted the Stx2-producing C. rodentium model to identify 365	  
potential therapeutics to reduce mortality and disease severity. Soluble 366	  
thrombomodulin is one possible therapeutic that has shown promising results in 367	  
pediatric patients with EHEC-induced HUS (Honda et al, 2013; Kawasaki et al, 368	  
2013). In this study, we examined the effects of sTM treatment on mice infected 369	  
with C. rodentium expressing Stx2 by examining survival, weight loss, 370	  
colonization, BUN, and acute kidney injury (AKI) markers NGAL and KIM-1. 371	  
 372	  
3.2 Material and Methods 373	  
3.2.1 Murine Model of EHEC Infection 374	  
Six-week old female C57BL/6J mice (Jackson Laboratory, Bar Harbor, 375	  
ME) were challenged with Citrobacter rodentium that expresses a Stx2 phage (Cr 376	  
Stx2+) or non-toxin expressing control phage (Cr WT) (Mallick et al, 2012). 377	  
Bacteria were grown in LB broth containing chloramphenicol (10 ug/ml; Cr Stx2+) 378	  
or both chloramphenicol and kanamycin (25 ug/ml; Cr WT) to an OD600 of 0.75- 379	  
1.0. This OD600 range corresponds to approximately 1x109 CFU/ml according to 380	  
an OD600 versus CFU standard curve. Bacteria were centrifuged and 381	  
resuspended in sterile saline. Mice were gavaged with approximately 1x109 CFU 382	  
in 100 ul of sterile saline. Inoculum concentration was determined by serial 383	  
dilution plating on appropriate restrictive antibiotic LB agar plates.  384	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Weight was monitored daily and blood was collected by facial vein bleed in 385	  
35mM of EDTA periodically. Samples were centrifuged and plasma stored at - 386	  
80oC until assay.  Mice were euthanized upon reaching euthanasia criteria (loss 387	  
of ≥15% body weight or behavioral changes). C. rodentium fecal shedding was 388	  
determined by serial dilution plating of fecal slurries (10%w/v in PBS) on LB agar 389	  
plates with appropriate restrictive antibiotics. Plates were incubated inverted 390	  
overnight at 32oC and bacterial colonies were counted the following day. Organs 391	  
harvested at necropsy were stored in either RNAlater (Ambion, Austin, TX) and 392	  
stored at -80oC or in 10% neutral buffered formalin for downstream tissue 393	  
processing. Plasma blood urea nitrogen (BUN) concentration was determined 394	  
using the QuantiChrom Urea Assay Kit (BioAssay Systems, Hayward, CA). 395	  
C. rodentium strains were generously provided by Dr. John M. Leong 396	  
(Department of Molecular Biology and Microbiology, Tufts University Medical 397	  
Center, Boston, MA). Animals were housed and used in accordance with 398	  
approved IACUC and IBC protocols from Boston University School of Medicine.   399	  
 400	  
3.2.2 Soluble Thrombomodulin 401	  
For recombinant human soluble thrombomodulin (sTM; Asahi Kasei 402	  
Pharma, Tokyo, Japan) experiments, mice were challenged as described above 403	  
and given daily IP injections of sTM (6 ug/g) until 9 days post infection. The 404	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recombinant sTM is purified from transformed Chinese hamster ovary cells and is 405	  
composed of the extracellular domain of TM (Gomi et al, 1990). 406	  
 407	  
3.2.3 RNA Isolation from Kidneys 408	  
Tissue samples stored at -80oC in RNAlater were thawed on ice. Tissue 409	  
pieces <20mg in weight were added to Buffer RLT (Qiagen, Hilden, Germany) 410	  
and 3.5% 2-merceptoethanol. Tissue was lysed using a 5mm stainless steel 411	  
bead in the Tissue Lyser II for 4 minutes at 25Hz (Qiagen). Total RNA was 412	  
isolated from tissue lysate using the RNeasy Plus Mini Kit (Qiagen) and QIAcube 413	  
(Qiagen) following the manufacturer’s instructions. RNA concentration was 414	  
quantified by a NanoDrop 2000c UV-Vis Spectrophotometer (Thermo Scientific, 415	  
Waltham, MA). 416	  
 417	  
3.2.4 Reverse Transcription 418	  
Total RNA was converted to cDNA using Quantifast Reverse Transcription 419	  
Kit (Qiagen) and Thermocycler (Applied Biosystems, Beverly, MA) following the 420	  
manufacturer’s instructions. A total RNA concentration of 250 ng was used for 421	  
each reaction. 422	  
 423	  
3.2.5 Quantitative PCR for NGAL and KIM-1 424	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Amplification of cDNA was performed in a Step One Plus qPCR machine 425	  
(Applied Biosystems) using a Quantifast SYBR Green PCR Kit (Qiagen) 426	  
according to manufacturer’s instructions. Primers sets (Integrated DNA 427	  
Technologies, Coralville, IA) for murine neutrophil gelatinase-associated lipocalin 428	  
(NGAL), kidney injury molecule-1 (KIM-1), and hypoxanthine guanine 429	  
phosphoribosyl transferase (HPRT) were used at a final concentration of 430	  
1uMol/liter and are listed in Table 3.1. Obtained cycle threshold (CT) values were 431	  
normalized as follows:  [(2CT gene)/(2CT HPRT)]/[total RNA in RT reaction]. 432	  
 433	  
3.2.6 Statistical Analysis 434	  
 Analysis of variance (ANOVA) tests followed by Tukey post tests were 435	  
performed using GraphPad Prism 5 (GraphPad Software, La Jolla, CA) to 436	  
compare data collected from Cr Stx2+ & sTM and Cr WT to either Cr Stx2+ or all 437	  
groups at different time points for multiple outcomes. This software was used to 438	  
determine significant differences among the groups of mice, if present.  439	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Table 3.1 Quantitative PCR Primers 440	  
 441	  
  442	  Target Orientation Primer sequence (5’-3’) NGAL Forward CCCTGTATGGAAGAACCAAGGA 
 Reverse CGGTGGGGACAGAGAAGATG 
KIM-1 Forward GGAGATACCTGGAGTAATCACACTG 
 Reverse TAGCCACGGTGCTCACAAGG 
HPRT Forward TGGGCTTACCTCACTGCTTTC 
 Reverse CCTGGTTCATCATCGCTAATCAC 
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3.3 Results and Discussion 443	  
 Citrobacter rodentium lysogenized with the Shiga toxin 2 gene carrying 444	  
phage produces mucus-activatable Stx, provides a model that features prototypic 445	  
A/E lesions during intestinal colonization, Stx-mediated weight loss and death, 446	  
renal dysfunction, and renal tubular injury similar to murine toxin injection models 447	  
(Mallick et al, 2012). Mice infected with approximately 1x109CFU/100ul of Cr 448	  
Stx2+ corresponded with mortality or severe disease warranting euthanasia 449	  
between 6 to 9 days after infection (Fig 3.1A). Control mice infected with non- 450	  
toxin producing C. rodentium (Cr WT) all survived and were euthanized on day 451	  
14 for sample collection (Fig 3.1A). Treatment with sTM on mice infected with Cr 452	  
Stx2+ did not alter overall survival outcome, but did delay death a few days (Fig 453	  
3.1A). The Stx2-producing C. rodentium model does not feature 454	  
thrombocytopenia and anemia seen in patients with HUS and most likely does 455	  
not benefit from the anti-coagulant properties associated with survival in patients 456	  
with EHEC-HUS (Mallick et al, 2012; Honda et al, 2013). Typical infection of mice 457	  
with Cr Stx2+ saw slight rise in weight between days 1 to 4 and declined 458	  
significantly by days 6 to 9 compared to Cr WT (Fig 3.1B). Mice infected with Cr 459	  
Stx2+ lost > 15% of their starting weight by 8 days after infection, whereas sTM 460	  
treatment mice lost >15% body weight by day 12 (Fig 3.1B). Although sTM mice 461	  
declined significantly by day 4 compared to no treatment Cr Stx2+ mice, the 462	  
weight loss was gradual and was significantly higher on Cr Stx2+ endpoint days 463	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8 and 9 (Fig 3.1B). Interestingly, sTM treatment did significantly decrease fecal 464	  
shedding of Cr Stx2+, with similar kinetics to Cr WT, compared to no treatment 465	  
Cr Stx2+ infected mice (Fig 3.1C). Neutralizing antibodies to Stx2 have been 466	  
shown to reduce colonization in mice infected with E. coli O157:H7 (Mohawk et 467	  
al, 2010). Although sTM does not have Stx2 neutralizing capabilities, the anti- 468	  
inflammatory and cytoprotective properties may contribute to decreased bacterial 469	  
burden in the intestines and extend survival. 470	  
 Soluble thrombomodulin improved kidney function in pediatric patients 471	  
with EHEC-HUS so we examined three markers of renal dysfunction. Treatment 472	  
with sTM did not decrease plasma levels of BUN compared to no treatment and 473	  
both Cr Stx2+ and Cr Stx2+ with sTM were significantly higher than Cr WT (Fig 474	  
3.2A). Humans and non-human primates express Gb3 on renal glomerular 475	  
endothelial cells and are the primary target from Stx2 injury (Stearns-Kurosawa 476	  
et al, 2013). Mice express Gb3 on renal epithelial cells in the proximal tubules, 477	  
distal tubules, and collecting duct so thrombocytopenia and anemia does not 478	  
manifest, as they are associated with endothelial injury from Stx2 (Tesh et al, 479	  
1993; Rutjes et al, 2002; Psotka et al, 2009). Both NGAL and KIM-1 are markers 480	  
for renal injury in the proximal tubules of human and mice (Ichimura et al, 1998; 481	  
Mishra et al, 2003). Treatment with sTM in Cr Stx2+ infected mice significantly 482	  
decreased mRNA level expression of NGAL and KIM-1 in kidneys harvested at 483	  
euthanasia compared to no treatment (Fig 3.2B,C). As expected, Cr WT infected 484	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mice showed no sign of renal pathology. Anti-Stx2 antibody rescues mice 485	  
injected with lethal doses of Stx2 and improves serum BUN levels (Sauter et al, 486	  
2008). Soluble thrombomodulin’s cytoprotective properties decreased renal 487	  
NGAL and KIM-1 expression but was not able to decrease BUN and prevent 488	  
kidney dysfunction caused by Stx2.  489	  
 Although sTM was not able to prevent mortality and kidney injury based on 490	  
BUN levels, it did delay weight loss and death, decrease NGAL and KIM-1 gene 491	  
expression, and decrease intestinal colonization of Cr Stx2+. Soluble 492	  
thrombomodulin has been shown to be a promising therapeutic in human HUS 493	  
patients and would be worth exploring in the non-human primate baboon toxemia 494	  
model of HUS. Baboons (Papio) injected with 50ng/kg of Stx2 develop full 495	  
spectrum HUS including thrombocytopenia, hemolytic anemia, and AKI with 496	  
glomerular endothelial injury (Stearns-Kurosawa et al, 2010). The effects of sTM 497	  
may be more significant in this model due to the coagulopathy and injury to the 498	  
renal glomerular endothelium. Soluble thrombomodulin treatment in Cr Stx2+ 499	  
infected mice requires further characterizing but is a promising therapeutic for the 500	  
treatment of EHEC induced HUS in human patients. 501	  
  502	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 503	  
Figure 3.1. Treatment with sTM in C. rodentium (Cr Stx2+) infected mice 504	  
delays mortality and decreases colonization.  Mice were infected with 505	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approximately 1x109CFU/100ul with either Cr WT ("; n=10), Cr Stx2+ (n; n=14), 506	  
or Cr Stx2+ & sTM (p; n=10). (A) Percent survival of groups of 6-week-old 507	  
C57BL/6 mice infected with either Cr WT, Cr Stx2+, or Cr Stx2+ with sTM 508	  
treatment. *** P<0.001 compared to Cr Stx2+ by 2-way ANOVA followed by 509	  
Tukey post tests. (B) Body weight during infection of 6-week-old mice, expressed 510	  
as percent change from day 0. Mean values and standard deviation are shown. * 511	  
P<0.05, ** P<0.01, **** P<0.0001 compared to Cr Stx2+ by 2-way ANOVA 512	  
followed by Tukey post tests (C) Colonization of 6-week-old mice determined by 513	  
viable stool counts. Mean values and standard deviation are shown. ** P<0.01, 514	  
**** P<0.0001 compared to Cr Stx2+ by 2-way ANOVA followed by Tukey post 515	  
tests. 516	  
 517	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Figure 3.2.  Treatment with sTM decreases kidney injury marker expression 520	  
but does not alter plasma BUN levels. Kidney injury was examined in mice 521	  
infected with Cr WT ("; n=10), Cr Stx2+ (n; n=10), or Cr Stx2+ & sTM (p; n=8). 522	  
(A) BUN of 6-week-old mice, each represented as a single data point, from 523	  
EDTA-plasma samples at day of necropsy. *** P<0.001, **** P<0.0001 compared 524	  
with all other groups by 1-way ANOVA followed by Tukey post tests. (B) and (C) 525	  
Measurement of AKI marker gene transcripts in kidneys. Each animal represents 526	  
a single data point. Kidney tissues were processed to obtain total RNA for the 527	  
generation of cDNA and qPCR was performed for the indicated gene as 528	  
described in Materials and Methods. * P<0.05, ** P<0.01, *** P<0.001 compared 529	  
with all other groups by 1-way ANOVA followed by Tukey post tests. 530	  
  531	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CHAPTER FOUR 532	  
SUMMARY AND CONCLUSION 533	  
In these studies, we have determined that (1) complement activation is not 534	  
required for the development of thrombotic microangiopathy and HUS induced by 535	  
EHEC Shiga toxins, and benefits or risks of therapeutic complement inhibition 536	  
should be carefully considered before applying in human EHEC patients; and (2) 537	  
soluble thrombomodulin treatment in mice infected with Stx2-producing C. 538	  
rodentium reduced renal cellular injury, but was not sufficient to alter mortality. 539	  
Both animal models feature the severe kidney injury caused by Shiga toxins and 540	  
highlight key pathology seen in human patients. Soluble thrombomodulin has 541	  
already been identified as a promising therapeutic in human patients with HUS 542	  
but should further be characterized in animal models of HUS and EHEC infection 543	  
to determine the pharmacodynamics and potential adverse side effects with 544	  
treatment. 545	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